Alzheimer’s Research Papers Jan 2001

Alzheimer’s Research Papers

Sharma M, Gupta YK. Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci. 2001 Jan 19;68(9):1021-9.

Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001 Jan 19;297(3):187-90.

Richard F, Amouyel P. Genetic susceptibility factors for Alzheimer's disease. Eur J Pharmacol. 2001 Jan 19;412(1):1-12.

Yao Z, Drieu K, Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 2001 Jan 19;889(1-2):181-90.

Sato N, Imaizumi K, Manabe T, Taniguchi M, Hitomi J, Katayama T, Yoneda T, Morihara T, Yasuda Y, Takagi T, Kudo T, Tsuda T, Itoyama Y, Makifuchi T, Fraser PE, St George-Hyslop P, Tohyama M. Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2. J Biol Chem. 2001 Jan 19;276(3):2108-14.

Sáez-Valero J, Small DH. Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in Alzheimer's disease. Brain Res. 2001 Jan 19;889(1-2):247-50. ,

Dahlin M, Björk E. Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats. Int J Pharm. 2001 Jan 16;212(2):267-74.

O'Brien J, Thomas A, Ballard C, Brown A, Ferrier N, Jaros E, Perry R. Cognitive impairment in depression is not associated with neuropathologic evidence of increased vascular or Alzheimer-type pathology. Biol Psychiatry. 2001 Jan 15;49(2):130-6.


Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001 Jan 15;20(1-2):27-39.
 

Baskin F, Rosenberg RN, Iyer L, Schellenberg GD, Hynan L, Nee LE. Platelet APP isoform ratios in asymptomatic young adults expressing an AD-related presenilin-1 mutation. J Neurol Sci. 2001 Jan 15;183(1):85-8.

Le Y, Gong W, Tiffany HL, Tumanov A, Nedospasov S, Shen W, Dunlop NM, Gao JL, Murphy PM, Oppenheim JJ, Wang JM. Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci. 2001 Jan 15;21(2):RC123.


Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001 Jan 15;21(2):372-81. ,
 

Nash JM. Alzheimer's disease. New insights into its cause lead to new drug strategies. Time. 2001 Jan 15;157(2):80-1, 85.

Hebert LE, Scherr PA, McCann JJ, Beckett LA, Evans DA. Is the risk of developing Alzheimer's disease greater for women than for men? Am J Epidemiol. 2001 Jan 15;153(2):132-6.
 


Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. Brain Res. 2001 Jan 12;888(2):287-296. ,
 


Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 2001 Jan 12;888(2):256-262.
 

Guo GW, Liang YX. Aluminum-induced apoptosis in cultured astrocytes and its effect on calcium homeostasis. Brain Res. 2001 Jan 12;888(2):221-226.

Yoo BC, Kim SH, Cairns N, Fountoulakis M, Lubec G. Deranged expression of molecular chaperones in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun. 2001 Jan 12;280(1):249-58.

Hino H, Akiyama H, Iseki E, Kato M, Kondo H, Ikeda K, Kosaka K. Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues. Neurosci Lett. 2001 Jan 12;297(2):105-8.


Yasojima K, Akiyama H, McGeer EG, McGeer PL. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett. 2001 Jan 12;297(2):97-100. ,
    

von Arnim CA, Ludolph AC. [Normal and pathological aging of the brain] Fortschr Med Orig. 2001 Jan 11;118(4):165-8.

Burneo JG, Papamitsakis NI, Mitsias PD. Cerebral ventricles are smaller in Hispanic than non-Hispanic patients with Alzheimer's disease. Neurology. 2001 Jan 9;56(1):139-40.

Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 2001 Jan 9;56(1):127-9. ,

Sánchez L, Alvarez V, González P, González I, Alvarez R, Coto E. Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease. Am J Med Genet. 2001 Jan 8;105(1):76-8. ,

Hyde LA, Frisone DF, Crnic LS. Ts65Dn mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function. Behav Brain Res. 2001 Jan 8;118(1):53-60.

Berger A. Vaccine improves memory in "Alzheimer's" mice. BMJ. 2001 Jan 6;322(7277):9.


Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;276(1):251-60.

Kim D, Koh WK, Kim JU, Lee JH, Hong HN. Okadaic acid-induced upregulation of nitrotyrosine and heme oxygenase-1 in rat cortical neuron cultures. Neurosci Lett. 2001 Jan 5;297(1):33-6.

Yoshida T, Tanaka M, Okamoto K. Inhibitory effect of nicergoline on superoxide generation by activated rat microglias measured using a simple chemiluminescence method. Neurosci Lett. 2001 Jan 5;297(1):5-8.

Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001 Jan 5;487(3):404-7.
 

Pinnix I, Musunuru U, Tun H, Sridharan A, Golde T, Eckman C, Ziani-Cherif C, Onstead L, Sambamurti K. A novel gamma -secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor. J Biol Chem. 2001 Jan 5;276(1):481-7.


Struhl G, Greenwald I. Presenilin-mediated transmembrane cleavage is required for Notch signal transduction in Drosophila. Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):229-34.

Bäckman L, Small BJ, Fratiglioni L. Stability of the preclinical episodic memory deficit in Alzheimer's disease. Brain. 2001 Jan;124(Pt 1):96-102.

Chorsky RL, Yaghmai F, Hill WD, Stopa EG. Alzheimer's disease: a review concerning immune response and microischemia. Med Hypotheses. 2001 Jan;56(1):124-7.

Jones GR. Causes of Alzheimer's disease: paracetamol (acetaminophen) today? Amphetamines tomorrow? Med Hypotheses. 2001 Jan;56(1):121-3.

Neill D, Hughes D, Leake A, Morris C, Jones D, Oakley A, Edwardson J, Estibeiro P. Neuritogenic-neurotoxic effects of membrane-associated forms of amyloid precursor protein. Dement Geriatr Cogn Disord. 2001 Jan-Feb;12(1):40-51.

Almkvist O, Jelic V, Amberla K, Hellström-Lindahl E, Meurling L, Nordberg A. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord. 2001 Jan-Feb;12(1):22-32.

Hirono N, Mori E, Ishii K, Imamura T, Tanimukai S, Kazui H, Hashimoto M, Takatsuki Y, Kitagaki H, Sasaki M. Neuronal substrates for semantic memory: a positron emission tomography study in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Jan-Feb;12(1):15-21.

Chemerinski E, Petracca G, Sabe L, Kremer J, Starkstein SE. The specificity of depressive symptoms in patients with Alzheimer's disease. Am J Psychiatry. 2001 Jan;158(1):68-72.

Shaji KS, Kishore NR, Praveenlal K. Information and education for carers of patients with Alzheimer's disease. Br J Psychiatry. 2001 Jan;178(1):83-4.

Liddell MB, Lovestone S, Owen MJ. Genetic risk of Alzheimer's disease: advising relatives. Br J Psychiatry. 2001 Jan;178(1):7-11.

Chodobski A, Szmydynger-Chodobska J. Choroid plexus: target for polypeptides and site of their synthesis. Microsc Res Tech. 2001 Jan 1;52(1):65-82.

Rypniewski WR, Ostergaard PR, Nørregaard-Madsen M, Dauter M, Wilson KS. Fusarium oxysporum trypsin at atomic resolution at 100 and 283 K: a study of ligand binding. Acta Crystallogr D Biol Crystallogr. 2001 Jan;57(Pt 1):8-19.


Kontush A, Berndt C, Weber W, Akopyan V, Arlt S, Schippling S, Beisiegel U. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med. 2001 Jan 1;30(1):119-28.

Fallin D, Cohen A, Essioux L, Chumakov I, Blumenfeld M, Cohen D, Schork NJ. Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. Genome Res. 2001 Jan;11(1):143-51.

Touchman JW, Dehejia A, Chiba-Falek O, Cabin DE, Schwartz JR, Orrison BM, Polymeropoulos MH, Nussbaum RL. Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome Res. 2001 Jan;11(1):78-86.


Pettit DL, Shao Z, Yakel JL. beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci. 2001 Jan 1;21(1):RC120.

Xu J, Chen S, Ahmed SH, Chen H, Ku G, Goldberg MP, Hsu CY. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci. 2001 Jan 1;21(1):RC118.

Pruessner JC, Collins DL, Pruessner M, Evans AC. Age and gender predict volume decline in the anterior and posterior hippocampus in early adulthood. J Neurosci. 2001 Jan 1;21(1):194-200.

Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol. 2001 Jan;13(1):67-73.

Standen CL, Brownlees J, Grierson AJ, Kesavapany S, Lau KF, McLoughlin DM, Miller CC. Phosphorylation of thr(668) in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by stress-activated protein kinase 1b (Jun N-terminal kinase-3). J Neurochem. 2001 Jan;76(1):316-20.

Olivieri G, Baysang G, Meier F, Müller-Spahn F, Stähelin HB, Brockhaus M, Brack C. N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation. J Neurochem. 2001 Jan;76(1):224-33.

Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp GM, Thorsett ED, Tung JS, Wu J, Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK, Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Little SP, Mabry TE, Miller FD, Audia JE. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001 Jan;76(1):173-81.
 

Drouet B, Fifre A, Pinçon-Raymond M, Vandekerckhove J, Rosseneu M, Guéant JL, Chambaz J, Pillot T. ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide. J Neurochem. 2001 Jan;76(1):117-27.

Dubal DB, Wise PM. Neuroprotective effects of estradiol in middle-aged female rats. Endocrinology. 2001 Jan;142(1):43-8.

Bayer TA, Wirths O, Majtényi K, Hartmann T, Multhaup G, Beyreuther K, Czech C. Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol. 2001 Jan;11(1):1-11.

Ebert U, Grossmann M, Oertel R, Gramatté T, Kirch W. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. J Clin Pharmacol. 2001 Jan;41(1):51-60.

Reich EE, Markesbery WR, Roberts LJ, Swift LL, Morrow JD, Montine TJ. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol. 2001 Jan;158(1):293-7.

Hall GF, Lee VM, Lee G, Yao J. Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy. Am J Pathol. 2001 Jan;158(1):235-46.
 

Rohn TT, Head E, Su JH, Anderson AJ, Bahr BA, Cotman CW, Cribbs DH. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol. 2001 Jan;158(1):189-98.

Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol. 2001 Jan;158(1):63-73.

Massi F, Peng JW, Lee JP, Straub JE. Simulation study of the structure and dynamics of the Alzheimer's amyloid peptide congener in solution. Biophys J. 2001 Jan;80(1):31-44.

Thomas T, Bryant M, Clark L, Garces A, Rhodin J. Estrogen and raloxifene activities on amyloid-beta-induced inflammatory reaction. Microvasc Res. 2001 Jan;61(1):28-39.

Wang YC, Tsai SJ, Liu TY, Liu HC, Hong CJ. No association between tryptophan hydroxylase gene polymorphism and Alzheimer's disease. Neuropsychobiology. 2001 Jan;43(1):1-4. ,

Santens P, De Bleecker J, Goethals P, Strijckmans K, Lemahieu I, Slegers G, Dierckx R, De Reuck J. Differential regional cerebral uptake of (18)F-fluoro-2-deoxy-D-glucose in Alzheimer's disease and frontotemporal dementia at initial diagnosis. Eur Neurol. 2001;45(1):19-27.

Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001;18(6):389-96.

Tsolaki M, Sakka V, Gerasimou G, Dimacopoulos N, Chatzizisi O, Fountoulakis KN, Kyriazis G, Papanastasiou J, Kazis A. Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects. Am J Alzheimers Dis Other Demen. 2001 Jan-Feb;16(1):21-31.

Iliev A, Traykov V, Stoykov I, Yakimova K. Estradiol inhibits astrocytic GFAP expression in an animal model of neuroinflammation. Methods Find Exp Clin Pharmacol. 2001 Jan-Feb;23(1):29-35.

Maddock RJ, Garrett AS, Buonocore MH. Remembering familiar people: the posterior cingulate cortex and autobiographical memory retrieval. Neuroscience. 2001;104(3):667-76.

Matsuoka Y, Picciano M, La Francois J, Duff K. Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience. 2001;104(3):609-13.

López-Arrieta JM, Rodríguez JL, Sanz F. Efficacy and safety of nicotine on Alzheimer's disease patients. Cochrane Database Syst Rev. 2001;(2):CD001749.

Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001;(2):CD001011.

Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. Cochrane Database Syst Rev. 2001;(2):CD000359.

Huppert FA, Van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function . Cochrane Database Syst Rev. 2001;(2):CD000304.

Gandy S, Petanceska S. Regulation of alzheimer beta-amyloid precursor trafficking and metabolism. Adv Exp Med Biol. 2001;487:85-100.

Probst A, Mistl C, Ipsen S, Tolnay M. Perisomatic granules of hippocampal CA1 neurons in Alzheimer's disease, pre-Alzheimer stage and Pick's disease: an overlooked pathological entity. Adv Exp Med Biol. 2001;487:187-98.

Yang SY, He XY. Role of type 10 17beta-hydroxysteroid dehydrogenase in the pathogenesis of Alzheimer's disease. Adv Exp Med Biol. 2001;487:101-10.

Rasmusen L, Yan B, Robillard A, Dunbar F. Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin Ther. 2001;23 Suppl A:A25-30.

Farlow MR. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Clin Ther. 2001;23 Suppl A:A13-24.

Coelho F, Birks J. Physostigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2001;(2):CD001499.

Ferris SH. Switching previous therapies for Alzheimer's disease to galantamine. Clin Ther. 2001;23 Suppl A:A3-7.

Morris JC. Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Introduction. Clin Ther. 2001;23 Suppl A:A1-2.

Honjo H, Kikuchi N, Hosoda T, Kariya K, Kinoshita Y, Iwasa K, Ohkubo T, Tanaka K, Tamura T, Urabe M, Kawata M. Alzheimer's disease and estrogen. J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):227-30.

Cummings JL. Treatment of Alzheimer's disease. Clin Cornerstone. 2001;3(4):27-39.

DeKosky ST. Epidemiology and pathophysiology of Alzheimer's disease. Clin Cornerstone. 2001;3(4):15-26.

Rodríguez-Martín JL, Qizilbash N, López-Arrieta JM. Thiamine for Alzheimer's disease. Cochrane Database Syst Rev. 2001;(2):CD001498.

Maelicke A. Pharmacokinetic rationale for switching from donepezil to galantamine. Clin Ther. 2001;23 Suppl A:A8-12.

Morris JC, Farlow MR, Ferris SH, Kurz AF, Maelicke A, Rasmusen L, Wilkinson D, Yan B. Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers. Clin Ther. 2001;23 Suppl A:A31-9.

Ijzerman A, Kourounakis A, van der Klein P. Allosteric modulation of G protein-coupled receptors. Farmaco. 2001 Jan-Feb;56(1-2):67-70.

Adler G, Brassen S. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology. 2001;43(4):273-6.

Allt G, Lawrenson JG. Pericytes: cell biology and pathology. Cells Tissues Organs. 2001;169(1):1-11.

Bennett A. Anti-inflammatory drugs, cyclooxygenases and other factors. Expert Opin Pharmacother. 2001 Jan;2(1):1-2.

Tsai SJ, Hong CJ, Liu TY, Cheng CY, Liu HC. Association study for a functional serotonin transporter gene polymorphism and late-onset Alzheimer's disease for Chinese patients. Neuropsychobiology. 2001;44(1):27-30. , ,

Rösler N, Wichart I, Jellinger KA. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. J Neural Transm. 2001;108(2):231-46. ,

Fukuta T, Nitta A, Itoh A, Furukawa S, Nabeshima T. Difference in toxicity of beta-amyloid peptide with aging in relation to nerve growth factor content in rat brain. J Neural Transm. 2001;108(2):221-30.

Dowjat WK, Wisniewski H, Wisniewski T. Alzheimer's disease presenilin-1 expression modulates the assembly of neurofilaments. Neuroscience. 2001;103(1):1-8.

Junceda-Moreno J, Junceda-Moreno C, Suárez-Suárez E, Vidal-Sánchez JA, Junceda-Avello JM. [The use of afterimages in the diagnosis of Alzheimer's disease] Rev Neurol. 2001 Jan 1-15;32(1):38-41.

Thomas A, Iacono D, Bonanni L, D'Andreamatteo G, Onofrj M. Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clin Neuropharmacol. 2001 Jan-Feb;24(1):31-42.

Tolnay M, Probst A. Frontotemporal lobar degeneration. An update on clinical, pathological and genetic findings. Gerontology. 2001 Jan-Feb;47(1):1-8.

Caine D, Patterson K, Hodges JR, Heard R, Halliday G. Severe anterograde amnesia with extensive hippocampal degeneration in a case of rapidly progressive frontotemporal dementia. Neurocase. 2001;7(1):57-64.

del Ser T, Hachinski V, Merskey H, Munoz DG. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord. 2001 Jan-Mar;15(1):31-44.

Davis RN, Massman PJ, Doody RS. Cognitive intervention in Alzheimer disease: a randomized placebo-controlled study. Alzheimer Dis Assoc Disord. 2001 Jan-Mar;15(1):1-9.

Mega MS, Cummings JL, O'Connor SM, Dinov ID, Reback E, Felix J, Masterman DL, Phelps ME, Small GW, Toga AW. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jan;14(1):63-8.

Luetjens CM, Lankiewicz S, Bui NT, Krohn AJ, Poppe M, Prehn JH. Up-regulation of Bcl-xL in response to subtoxic beta-amyloid: role in neuronal resistance against apoptotic and oxidative injury. Neuroscience. 2001;102(1):139-50.

Weis C, Marksteiner J, Humpel C. Nerve growth factor and glial cell line-derived neurotrophic factor restore the cholinergic neuronal phenotype in organotypic brain slices of the basal nucleus of Meynert. Neuroscience. 2001;102(1):129-38.

Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem. 2001 Jan;76(2):435-41.

Jonnala RR, Buccafusco JJ. Inhibition of nerve growth factor signaling by peroxynitrite. J Neurosci Res. 2001 Jan 1;63(1):27-34.

Rachal Pugh C, Fleshner M, Watkins LR, Maier SF, Rudy JW. The immune system and memory consolidation: a role for the cytokine IL-1beta. Neurosci Biobehav Rev. 2001 Jan;25(1):29-41.

Aoba A. [Clinical stage of dementia of Alzheimer's type] Nippon Ronen Igakkai Zasshi. 2001 Jan;38(1):85-7.

Laskowitz DT, Thekdi AD, Thekdi SD, Han SK, Myers JK, Pizzo SV, Bennett ER. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol. 2001 Jan;167(1):74-85.

Stopa EG, Berzin TM, Kim S, Song P, Kuo-Leblanc V, Rodriguez-Wolf M, Baird A, Johanson CE. Human choroid plexus growth factors: What are the implications for CSF dynamics in Alzheimer's disease? Exp Neurol. 2001 Jan;167(1):40-7.

Power JM, Oh MM, Disterhoft JF. Metrifonate decreases sI(AHP) in CA1 pyramidal neurons in vitro. J Neurophysiol. 2001 Jan;85(1):319-22.

Doty RL. Olfaction. Annu Rev Psychol. 2001;52:423-52.

Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J Neurol Sci. 2001 Jan 1;182(2):151-9.

Villatte F, Bachman TT, Hussein AS, Schmid RD. Acetylcholinesterase assay for rapid expression screening in liquid and solid media. Biotechniques. 2001 Jan;30(1):81-4, 86.

Kemppainen N, Marjamäki P, Röyttä M, Rinne JO. Different pattern of reduction of striatal dopamine reuptake sites in Alzheimer's disease and ageing. J Neural Transm. 2001;108(7):827-36.

Nihashi T, Inao S, Kajita Y, Kawai T, Sugimoto T, Niwa M, Kabeya R, Hata N, Hayashi S, Yoshida J. Expression and distribution of beta amyloid precursor protein and beta amyloid peptide in reactive astrocytes after transient middle cerebral artery occlusion. Acta Neurochir (Wien). 2001;143(3):287-95.

Iznak AF, Gorbachevskaia NL, Zhigul'skaia SE, Grigor'eva NV, Grachev VV, Vasil'eva AG, Chaianov NV, Gavrilova SI, Roshchina IF, Kolykhalov IV, Bashina VM, Simashkova NV. [Quantitative EEG correlates of the human frontal lobe dysfunction] Vestn Ross Akad Med Nauk. 2001;(7):48-53.

Rípová D, Strunecká A. An ideal biological marker of Alzheimer's disease: dream or reality? Physiol Res. 2001;50(2):119-29.

Copani A, Condorelli F, Canonico PL, Nicoletti F, Sortino MA. Cell cycle progression towards Alzheimer's disease. Funct Neurol. 2001;16(4 Suppl):11-5.

Govoni S, Lanni C, Racchi M. Advances in understanding the pathogenetic mechanisms of Alzheimer's disease. Funct Neurol. 2001;16 Suppl 4:17-30.

Werber AE, Klein C, Rabey JM. Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials. Neurol Neurochir Pol. 2001;35 Suppl 3:37-43.

Govoni S, Lanni C, Racchi M. Advances in understanding the pathogenetic mechanisms of Alzheimer's disease. Funct Neurol. 2001;16(4 Suppl):17-30.

Cavelier L, Erikson I, Tammi M, Jalonen P, Lindholm E, Jazin E, Smith P, Luthman H, Gyllensten U. MtDNA mutations in maternally inherited diabetes: presence of the 3397 ND1 mutation previously associated with Alzheimer's and Parkinson's disease. Hereditas. 2001;135(1):65-70.

Jellinger KA. Cell death mechanisms in neurodegeneration. J Cell Mol Med. 2001 Jan-Mar;5(1):1-17.
 

Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2001;(1):CD001747.

Hodges JR, Miller B. The neuropsychology of frontal variant frontotemporal dementia and semantic dementia. Introduction to the special topic papers: Part II. Neurocase. 2001;7(2):113-21.

Gauthier S. Alzheimer's disease: current and future therapeutic perspectives. Prog Neuropsychopharmacol Biol Psychiatry. 2001 Jan;25(1):73-89.

Pepeu G. Overview and perspective on the therapy of Alzheimer's disease from a preclinical viewpoint. Prog Neuropsychopharmacol Biol Psychiatry. 2001 Jan;25(1):193-209.

Bryant J, Clegg A, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess. 2001;5(1):1-137.

Kunugi H, Ueki A, Otsuka M, Isse K, Hirasawa H, Kato N, Nabika T, Kobayashi S, Nanko S. A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease. Mol Psychiatry. 2001 Jan;6(1):83-6. ,

Roizen NJ. Down syndrome: progress in research. Ment Retard Dev Disabil Res Rev. 2001;7(1):38-44.

Weissig V, Torchilin VP. Towards mitochondrial gene therapy: DQAsomes as a strategy. J Drug Target. 2001;9(1):1-13.

Dworetzky BA. The neurology of memory. Semin Speech Lang. 2001;22(2):95-105.

Cutler NR, Sramek JJ. Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development. Prog Neuropsychopharmacol Biol Psychiatry. 2001 Jan;25(1):27-57.

Gorman PM, Chakrabartty A. Alzheimer beta-amyloid peptides: Structures of amyloid fibrils and alternate aggregation products. Biopolymers. 2001;60(5):381-94.
 

Owen JE, Goode KT, Haley WE. End of life care and reactions to death in African-American and white family caregivers of relatives with Alzheimer's disease. Omega (Westport). 2001;43(4):349-61.

Thorpe JR, Morley SJ, Rulten SL. Utilizing the peptidyl-prolyl cis-trans isomerase pin1 as a probe of its phosphorylated target proteins. Examples of binding to nuclear proteins in a human kidney cell line and to tau in Alzheimer's diseased brain. J Histochem Cytochem. 2001 Jan;49(1):97-108.

Lin WR, Wozniak MA, Esiri MM, Klenerman P, Itzhaki RF. Herpes simplex encephalitis: involvement of apolipoprotein E genotype. J Neurol Neurosurg Psychiatry. 2001 Jan;70(1):117-9.

Cappa A, Calcagni ML, Villa G, Giordano A, Marra C, De Rossi G, Puopolo M, Gainotti G. Brain perfusion abnormalities in Alzheimer's disease: comparison between patients with focal temporal lobe dysfunction and patients with diffuse cognitive impairment. J Neurol Neurosurg Psychiatry. 2001 Jan;70(1):22-7.

Lamb HM, Goa KL. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics. 2001;19(3):303-18.

Warrington EK, Agnew SK, Kennedy AM, Rossor MN. Neuropsychological profiles of familial Alzheimer's disease associated with mutations in the presenilin 1 and amyloid precursor protein genes. J Neurol. 2001 Jan;248(1):45-50.

Serot JM, Christmann D, Dubost T, Béne MC, Faure GC. CSF-folate levels are decreased in late-onset AD patients. J Neural Transm. 2001;108(1):93-9.

Sukhanov AV, Korolenko TsP, Vinogradova TE, Voevoda MI. [Molecular genetic risk factors of Alzheimer's disease] Zh Nevrol Psikhiatr Im S S Korsakova. 2001;101(1):65-8.

Levy E, Sastre M, Kumar A, Gallo G, Piccardo P, Ghetti B, Tagliavini F. Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol. 2001 Jan;60(1):94-104.
 

Askanas V, Engel WK. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol. 2001 Jan;60(1):1-14.

Ferrer I, Blanco R, Carmona M, Puig B, Ribera R, Rey MJ, Ribalta T. Prion protein expression in senile plaques in Alzheimer's disease. Acta Neuropathol (Berl). 2001 Jan;101(1):49-56.

Takeda A, Wakai M, Niwa H, Dei R, Yamamoto M, Li M, Goto Y, Yasuda T, Nakagomi Y, Watanabe M, Inagaki T, Yasuda Y, Miyata T, Sobue G. Neuronal and glial advanced glycation end product [Nepsilon-(carboxymethyl)lysine]] in Alzheimer's disease brains. Acta Neuropathol (Berl). 2001 Jan;101(1):27-35.

Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol (Berl). 2001 Jan;101(1):2-8.

Rojas-Fernandez CH, Lanctot KL, Allen DD, MacKnight C. Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm? Pharmacotherapy. 2001 Jan;21(1):74-102.

Mazzola JL, Sirover MA. Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. J Neurochem. 2001 Jan;76(2):442-9.


Fan QW, Yu W, Senda T, Yanagisawa K, Michikawa M. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem. 2001 Jan;76(2):391-400.
 

Kumar VB, Vyas K, Franko M, Choudhary V, Buddhiraju C, Alvarez J, Morley JE. Molecular cloning, expression, and regulation of hippocampal amyloid precursor protein of senescence accelerated mouse (SAMP8). Biochem Cell Biol. 2001;79(1):57-67.

Gulesserian T, Seidl R, Hardmeier R, Cairns N, Lubec G. Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med. 2001 Jan;49(1):41-6.

Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm. 2001;108(4):459-73.

Hong CJ, Wang YC, Liu TY, Liu HC, Tsai SJ. A study of alpha-adrenoceptor gene polymorphisms and Alzheimer disease. J Neural Transm. 2001;108(4):445-50. ,

Nakamura M. [Alzheimer disease, familial] Ryoikibetsu Shokogun Shirizu. 2001;(33):168-9.

Fukuyama R, Izumoto T, Fushiki S. The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia. Eur Neurol. 2001;46(1):35-8. ,

Monteiro IM, Boksay I, Auer SR, Torossian C, Ferris SH, Reisberg B. Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer's Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability. Eur Psychiatry. 2001 Jan;16 Suppl 1:5s-24s.

Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs. 2001;15(5):375-90.

Kölsch H, Ludwig M, Lütjohann D, Rao ML. Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17beta. J Neural Transm. 2001;108(4):475-88.

Sjögren M, Hesse C, Basun H, Köl G, Thostrup H, Kilander L, Marcusson J, Edman A, Wallin A, Karlsson I, Troell M, Wachtmaister G, Ekdahl A, Olofsson H, Sandström A, Andreasen N, Minthon L, Blennow K. Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype. J Neural Transm. 2001;108(4):451-8.

Okamoto M, Nakajima Y, Matsuyama T, Sugita M. Amyloid precursor protein associates independently and collaboratively with PTB and PDZ domains of mint on vesicles and at cell membrane. Neuroscience. 2001;104(3):653-65.

Hoozemans JJ, Rozemuller AJ, Veerhuis R, Eikelenboom P. Immunological aspects of alzheimer's disease: therapeutic implications. BioDrugs. 2001;15(5):325-37.

Ferencik M, Novak M, Rovensky J, Rybar I. Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs. Bratisl Lek Listy. 2001;102(3):123-32.

Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? CNS Drugs. 2001;15(2):85-91.

López-Arrieta , Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2001;(1):CD000147.

Mega MS. Differential diagnosis of dementia: clinical examination and laboratory assessment. Clin Cornerstone. 2001;3(4):1-14.

Spada RS, Ferri R, Roccasalva G, Toscano G, Cosentino FI. Lipoprotein(a), vascular dementia and Alzheimer's disease. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:369-373.

Panza F, Colacicco AM, Basile AM, Capurso C, D'Introno A, Mastroianni F, Scicutella G, Capurso A, Solfruzzi V. Impact of decreased frequency of apolipoprotein E varepsilon4 allele on Alzheimer's disease in Southern Italy. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:299-306.

Nacmias B, Tedde A, Forleo P, Piacentini S, Latorraca S, Guarnieri BM, Ortenzi L, Bartoli A, Petruzzi C, Serio A, Sorbi S. Psychosis, serotonin receptor polymorphism and Alzheimer's disease. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:279-283.

Moretti R, Torre P, Antonello RM, Cazzato G. Fronto-temporal dementia versus Alzheimer disease. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:273-278.

Licastro F. Genetic background of inflammatory molecules affects protein expression, the risk of developing Alzheimer's disease and cognitive decline. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:227-234.

Fuschillo C, La Pia S, Campana F, Pinto A, De Simone L. Cognitive deficits in Alzheimer's disease: Treatment with acetylcholinesterase inhibitor agents. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:151-158.

Thompson PM, Mega MS, Woods RP, Zoumalan CI, Lindshield CJ, Blanton RE, Moussai J, Holmes CJ, Cummings JL, Toga AW. Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cereb Cortex. 2001 Jan;11(1):1-16.

Gottfries CG. Late life depression. Eur Arch Psychiatry Clin Neurosci. 2001;251 Suppl 2:II57-61.

Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience. 2001;105(1):99-107.

Th'ng JP. Histone modifications and apoptosis: cause or consequence? Biochem Cell Biol. 2001;79(3):305-11.

Kaneko I, Morimoto K, Kubo T. Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: conversion of non-toxic [D-Ser(26)]beta-amyloid 1-40 to toxic and proteinase-resistant fragments. Neuroscience. 2001;104(4):1003-11.

Pilger C, Bartolucci C, Lamba D, Tropsha A, Fels G. Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking. J Mol Graph Model. 2001;19(3-4):288-96, 374-8.

Fraser PE, Yu G, Lévesque L, Nishimura M, Yang DS, Mount HT, Westaway D, St George-Hyslop PH. Presenilin function: connections to Alzheimer's disease and signal transduction. Biochem Soc Symp. 2001;(67):89-100.

Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S, Octave JN, Pradier L, Touchet N, Tremp G. Neurofibrillary tangles and tau phosphorylation. Biochem Soc Symp. 2001;(67):81-8.

Anderton BH, Betts J, Blackstock WP, Brion JP, Chapman S, Connell J, Dayanandan R, Gallo JM, Gibb G, Hanger DP, Hutton M, Kardalinou E, Leroy K, Lovestone S, Mack T, Reynolds CH, Van Slegtenhorst M. Sites of phosphorylation in tau and factors affecting their regulation. Biochem Soc Symp. 2001;(67):73-80.

Goedert M, Spillantini MG. Tau gene mutations and neurodegeneration. Biochem Soc Symp. 2001;(67):59-71.

Neve RL, McPhie DL, Chen Y. Alzheimer's disease: dysfunction of a signalling pathway mediated by the amyloid precursor protein? Biochem Soc Symp. 2001;(67):37-50.

Georgopoulou N, McLaughlin M, McFarlane I, Breen KC. The role of post-translational modification in beta-amyloid precursor protein processing. Biochem Soc Symp. 2001;(67):23-36.

Dewachter I, Moechars D, Van Dorpe J, Tesseur I, Van den Haute C, Spittaels K, Van Leuven F. Modelling Alzheimer's disease in multiple transgenic mice. Biochem Soc Symp. 2001;(67):203-10.

Duff K. Transgenic mouse models of Alzheimer's disease: phenotype and mechanisms of pathogenesis. Biochem Soc Symp. 2001;(67):195-202.

O'Neill C, Cowburn RF, Bonkale WL, Ohm TG, Fastbom J, Carmody M, Kelliher M. Dysfunctional intracellular calcium homoeostasis: a central cause of neurodegeneration in Alzheimer's disease. Biochem Soc Symp. 2001;(67):177-94.

Cowburn RF, O'Neill C, Bonkale WL, Ohm TG, Fastbom J. Receptor-G-protein signalling in Alzheimer's disease. Biochem Soc Symp. 2001;(67):163-75.

Mattson MP, Gary DS, Chan SL, Duan W. Perturbed endoplasmic reticulum function, synaptic apoptosis and the pathogenesis of Alzheimer's disease. Biochem Soc Symp. 2001;(67):151-62.

Yan SD, Schmidt AM, Stern D. Alzheimer's disease: inside, outside, upside down. Biochem Soc Symp. 2001;(67):15-22.

Anderson I, Adinolfi C, Doctrow S, Huffman K, Joy KA, Malfroy B, Soden P, Rupniak HT, Barnes JC. Oxidative signalling and inflammatory pathways in Alzheimer's disease. Biochem Soc Symp. 2001;(67):141-9.

von der Kammer H, Demiralay C, Andresen B, Albrecht C, Mayhaus M, Nitsch RM. Regulation of gene expression by muscarinic acetylcholine receptors. Biochem Soc Symp. 2001;(67):131-40.

Ohm TG, Hamker U, Cedazo-Minguez A, Röckl W, Scharnagl H, März W, Cowburn R, Müller W, Meske V. Apolipoprotein E and beta A4-amyloid: signals and effects. Biochem Soc Symp. 2001;(67):121-9.

Lovestone S, Anderton B, Betts J, Dayanandan R, Gibb G, Ljungberg C, Pearce J. Apolipoprotein E gene and Alzheimer's disease: is tau the link? Biochem Soc Symp. 2001;(67):111-20.

Strittmatter WJ. Apolipoprotein E and Alzheimer's disease: signal transduction mechanisms. Biochem Soc Symp. 2001;(67):101-9.

Allsop D, Twyman LJ, Davies Y, Moore S, York A, Swanson L, Soutar I. Modulation of beta-amyloid production and fibrillization. Biochem Soc Symp. 2001;(67):1-14.

Løkkegaard A, Nyengaard JR, West MJ. Stereological estimates of number and length of capillaries in subdivisions of the human hippocampal region. Hippocampus. 2001;11(6):726-40.

Ferrer I, Blanco R, Carmona M, Puig B. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm. 2001;108(12):1397-415.

Nadlinger K, Birkmayer J, Gebauer F, Kunze R. Influence of reduced nicotinamide adenine dinucleotide on the production of interleukin-6 by peripheral human blood leukocytes. Neuroimmunomodulation. 2001;9(4):203-8.

Höschl C, Hajek T. Hippocampal damage mediated by corticosteroids--a neuropsychiatric research challenge. Eur Arch Psychiatry Clin Neurosci. 2001;251 Suppl 2:II81-8.

Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97.
 

Zdrojewicz Z, Ciszko B. [Dehydroepiandrosterone (DHEA)--structure, clinical importance and the role in human body] Postepy Hig Med Dosw. 2001;55(6):835-54.

Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K, Yamaguchi T. beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease. Neuroscience. 2001;104(2):299-310.

Williams JH. Frequency-specific effects of flicker on recognition memory. Neuroscience. 2001;104(2):283-6.

Fernández- Lastra A, Morales-Rodríguez M, Penzol-Díaz J. [Neurophysiological study and use of P300 evoked potentials for investigation in the diagnosis and of follow-up of patients with Alzheimer s disease] Rev Neurol. 2001 Mar 16-31;32(6):525-8.

Ojaimi J, Byrne E. Mitochondrial function and alzheimer's disease. Biol Signals Recept. 2001 May-Aug;10(3-4):254-62.

Nishimura AL, Oliveira JR, Otto PA, Matioli SR, Brito-Marques PR, Bahia VS, Nitrini R, Zatz M. No evidence of association between the D10S1423 locus and Alzheimer disease in Brazilian patients. J Neural Transm. 2001;108(3):305-10.

Savoiardo M, Grisoli M. Imaging dementias. Eur Radiol. 2001;11(3):484-92.

Kalaria RN, Ballard CG, Ince PG, Kenny RA, McKeith IG, Morris CM, O'Brien JT, Perry EK, Perry RH, Edwardson JA. Multiple substrates of late-onset dementia: implications for brain protection. Novartis Found Symp. 2001;235:49-60; discussion 60-5.

Bush AI, Goldstein LE. Specific metal-catalysed protein oxidation reactions in chronic degenerative disorders of ageing: focus on Alzheimer's disease and age-related cataracts. Novartis Found Symp. 2001;235:26-38; discussion 38-43.

Effros RB. Ageing and the immune system. Novartis Found Symp. 2001;235:130-9; discussion 139-45, 146-9.

Tsolaki M, Pantazi T, Kazis A. Efficacy of acetylcholinesterase inhibitors versus nootropics in Alzheimer's disease: a retrospective, longitudinal study. J Int Med Res. 2001 Jan-Feb;29(1):28-36.

Ferrer I, Blanco R, Carmona M, Puig B, Barrachina M, Gómez C, Ambrosio S. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J Neural Transm. 2001;108(12):1383-96.

Jones LA, Akhtar S, Wann KT. Induction of Alzheimer phenotype in mouse skin fibroblasts. Proc West Pharmacol Soc. 2001;44:177-80.

Corbo RM, Scacchi R, Vilardo T, Ruggeri M. Polymorphisms in the apolipoprotein E gene regulatory region in relation to coronary heart disease and their effect on plasma apolipoprotein E. Clin Chem Lab Med. 2001 Jan;39(1):2-6.

Duker NJ, Sperling J, Soprano KJ, Druin DP, Davis A, Ashworth R. beta-Amyloid protein induces the formation of purine dimers in cellular DNA. J Cell Biochem. 2001;81(3):393-400.

Milanese M, Lkhayat MI, Zatta P. Inhibitory effect of aluminum on dopamine beta-hydroxylase from bovine adrenal gland. J Trace Elem Med Biol. 2001;15(2-3):139-41.

Novella JL, Jochum C, Jolly D, Morrone I, Ankri J, Bureau F, Blanchard F. Agreement between patients' and proxies' reports of quality of life in Alzheimer's disease. Qual Life Res. 2001;10(5):443-52.

Rivière S, Gillette-Guyonnet S, Voisin T, Reynish E, Andrieu S, Lauque S, Salva A, Frisoni G, Nourhashemi F, Micas M, Vellas B. A nutritional education program could prevent weight loss and slow cognitive decline in Alzheimer's disease. J Nutr Health Aging. 2001;5(4):295-9.

Della Sala S, Cocchini G. Theoretical and practical implications of dual task performance in Alzheimer Disease. Rev Neurol (Paris). 2001;157 Suppl 10:33-4.

Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in Alzheimer treatment. Rev Neurol (Paris). 2001;157 Suppl 10:31.

De Strooper B, Annaert W. The cell biology of Alzheimer's Disease. Rev Neurol (Paris). 2001;157 Suppl 10:25-6.

González González JA. [Drug treatment of Alzheimer's disease] An R Acad Nac Med (Madr). 2001;118(3):527-41; discussion 541-4.

Cheon MS, Fountoulakis M, Cairns NJ, Dierssen M, Herkner K, Lubec G. Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease. J Neural Transm Suppl. 2001;(61):281-8.

Kim SH, Nairn AC, Cairns N, Lubec G. Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease. J Neural Transm Suppl. 2001;(61):263-72.

Kim SH, Fountoulakis M, Cairns N, Lubec G. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl. 2001;(61):223-35.

Balcz B, Kirchner L, Cairns N, Fountoulakis M, Lubec G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm Suppl. 2001;(61):193-201.

Nelson PG, McCune SK, Ades AM, Nelson KB. Glial-neurotrophic mechanisms in Down syndrome. J Neural Transm Suppl. 2001;(61):85-94.

Sawa A. Alteration of gene expression in Down's syndrome (DS) brains: its significance in neurodegeneration. J Neural Transm Suppl. 2001;(61):361-71.

Cairns NJ. Molecular neuropathology of transgenic mouse models of Down syndrome. J Neural Transm Suppl. 2001;(61):289-301.
 

Bernert G, Sustrova M, Sovcikova E, Seidl R, Lubec G. Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome. J Neural Transm Suppl. 2001;(61):237-45.

Kitzmueller E, Greber S, Fountoulakis M, Lubec G. Carbohydrate handling enzymes in fetal Down syndrome brain. J Neural Transm Suppl. 2001;(61):203-10.

Thome J, Retz W, Baader M, Pesold B, Hu M, Cowen M, Durany N, Adler G, Henn FA, Rösler M. Association analysis of HTR6 and HTR2A polymorphisms in sporadic Alzheimer's disease. J Neural Transm. 2001;108(10):1175-80. ,

Sabbagh MN, Reid RT, Hansen LA, Alford M, Thal LJ. Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies. J Neural Transm. 2001;108(10):1149-57.

Serra JA, Domínguez RO, de Lustig ES, Guareschi EM, Famulari AL, Bartolomé EL, Marschoff ER. Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J Neural Transm. 2001;108(10):1135-48.

Kogan EA, Korczyn AD, Virchovsky RG, Klimovizky SSh , Treves TA, Neufeld MY. EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. J Neural Transm. 2001;108(10):1167-73.

Eckert GP, Wood WG, Müller WE. Effects of aging and beta-amyloid on the properties of brain synaptic and mitochondrial membranes. J Neural Transm. 2001;108(8-9):1051-64.

Reid RT, Sabbagh MN, Thal LJ. Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease. J Neural Transm. 2001;108(8-9):1043-50.

Payão SL, de Carvalho CV, da Silva ER, Lopes C, Markus RP, Winter LM, Smith MA. Pinealectomy-associated decrease in ribosomal gene activity in rats. Biogerontology. 2001;2(2):105-8.

Bobek-Billewicz B, Dziewiatkowski J, Hermann M. Magnetic resonance volumetric study of the temporal lobe structures in ischaemic vascular dementia. Folia Neuropathol. 2001;39(1):15-8.

Opala G, Jasinska-Myga B, Ochudlo S, Janiec K. [Diagnostic problems in the case of dementia with coexisting hematological disorders] Wiad Lek. 2001;54(7-8):456-61.

Francis LP. Alzheimer's disease: an issue for women's health care. J Gend Specif Med. 2001;4(3):6-9.

Barra V, Briandet P, Boire JY. Fusion in medical imaging: theory, interests and industrial applications. Medinfo. 2001;10(Pt 2):896-900.

Parnowski T. [The use of acetylcholinesterase inhibitors in Alzheimer's disease] Przegl Lek. 2001;58 Suppl 3:2-6.

Kim KW, Jhoo JH, Lee JH, Lee KU, Lee DY, Youn JC, Youn JY, Woo JI. Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer's disease in Koreans. J Neural Transm. 2001;108(10):1159-66. ,

Studer R, Baysang G, Brack C. N-Acetyl-L-Cystein downregulates beta-amyloid precursor protein gene transcription in human neuroblastoma cells. Biogerontology. 2001;2(1):55-60.

Wang M, Bäckström T, Sundström I, Wahlström G, Olsson T, Zhu D, Johansson IM, Björn I, Bixo M. Neuroactive steroids and central nervous system disorders. Int Rev Neurobiol. 2001;46:421-59.

De Deyn PP, Wirshing WC. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry. 2001;62 Suppl 21:19-22.

Takeda M. [Present status and future aspects of studies in Alzheimer disease] Seishin Shinkeigaku Zasshi. 2001;103(6):463-9.

Dukic-Stefanovic S, Schinzel R, Riederer P, Münch G. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology. 2001;2(1):19-34.

Gueguen Y, Bertrand P, Ferrari L, Batt AM, Siest G. Control of apolipoprotein E secretion by 25-hydroxycholesterol and proinflammatory cytokines in the human astrocytoma cell line CCF-STTG1. Cell Biol Toxicol. 2001;17(3):191-9.

Gencik M, Dahmen N, Wieczorek S, Kasten M, Gencikova A, Epplen JT. ApoE polymorphisms in narcolepsy. BMC Med Genet. 2001;2(1):9.

Duckett L. Alzheimer's dementia: morbidity and mortality. J Insur Med. 2001;33(3):227-34.

Vollmann J. Advance directives in patients with Alzheimer's disease. Ethical and clinical considerations. Med Health Care Philos. 2001;4(2):161-7.

Deleu D. Rivastigmine in the treatment of Alzheimer's disease. Eur Neurol. 2001;46(2):110.

Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I, Hernández G, Sol JM, Peña-Casanova J, NORMACODEM Group. NORMAlisation of Cognitive and Functional Instruments for DEMentia. Clinical validity of the 'mini-mental state' for Spanish speaking communities. Neuropsychologia. 2001;39(11):1150-7.

Miguel-Hidalgo JJ. SB-271046 (SmithKline Beecham). Curr Opin Investig Drugs. 2001 Jan;2(1):118-22.

Burbaeva GSh, Boksha IS, Turishcheva MS, Savushkina OK, Tereshkina EB, Vorob'eva EA. [Impaired cerebral glutamate metabolism in mental diseases (Alzheimer's disease, schizophrenia] Vestn Ross Akad Med Nauk. 2001;(7):34-7.

Gavrilova SI, Zharikov GA. [Current strategies of pathogenetic therapy of Alzheimer's disease] Vestn Ross Akad Med Nauk. 2001;(7):13-8.

Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121-59.

Demery JA, Hanlon RE, Bauer RM. Profound amnesia and confabulation following traumatic brain injury. Neurocase. 2001;7(4):295-302.

Roubertoux PL, Le Roy-Duflos I. Quantitative trait locus mapping: fishing strategy or replicable results? Behav Genet. 2001 Jan;31(1):141-8.

Ramirez MJ, Ridley RM, Baker HF, Maclean CJ, Honer WG, Francis PT. Chronic elevation of amyloid precursor protein in the neocortex or hippocampus of marmosets with selective cholinergic lesions. J Neural Transm. 2001;108(7):809-26.

Nicolas AS, Vellas B. Diet-related prevention of Alzheimer's disease: different hypotheses. Nestle Nutr Workshop Ser Clin Perform Programme. 2001;(5):219-27; discussion 228-30.

Preobrazhenskaia IS, Chekhonin VP, Iakhno NN. [Permeability of hemato-encephalic barrier in Alzheimer's disease and parkinsonism with cognitive disorders] Zh Nevrol Psikhiatr Im S S Korsakova. 2001;101(5):39-42.

Mikkonen M, Soininen H, Alafuzof I, Miettinen R. Hippocampal plasticity in Alzheimer's disease. Rev Neurosci. 2001;12(4):311-25.

Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging. 2001;18(11):853-62.

Yoo BC, Fountoulakis M, Dierssen M, Lubec G. Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down syndrome: dysregulation of T-complex protein 1. J Neural Transm Suppl. 2001;(61):321-34.

Seidl R, Cairns N, Lubec G. The brain in Down syndrome. J Neural Transm Suppl. 2001;(61):247-61.

Engidawork E, Gulesserian T, Balic N, Cairns N, Lubec G. Changes in nicotinic acetylcholine receptor subunits expression in brain of patients with Down syndrome and Alzheimer's disease. J Neural Transm Suppl. 2001;(61):211-22.

Engidawork E, Gulesserian T, Seidl R, Cairns N, Lubec G. Expression of apoptosis related proteins: RAIDD, ZIP kinase, Bim/BOD, p21, Bax, Bcl-2 and NF-kappaB in brains of patients with Down syndrome. J Neural Transm Suppl. 2001;(61):181-92.

Engidawork E, Balic N, Juranville JF, Fountoulakis M, Dierssen M, Lubec G. Unaltered expression of Fas (CD95/APO-1), caspase-3, Bcl-2 and annexins in brains of fetal Down syndrome: evidence against increased apoptosis. J Neural Transm Suppl. 2001;(61):149-62.

Kim SH, Lubec G. Decreased alpha-endosulfine, an endogenous regulator of ATP-sensitive potassium channels, in brains from adult Down syndrome patients. J Neural Transm Suppl. 2001;(61):1-9.

Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm. 2001;108(11):1319-25.

Carpenter DO. Effects of metals on the nervous system of humans and animals. Int J Occup Med Environ Health. 2001;14(3):209-18.

Bajo M, Yoo BC, Cairns N, Gratzer M, Lubec G. Neurofilament proteins NF-L, NF-M and NF-H in brain of patients with Down syndrome and Alzheimer's disease. Amino Acids. 2001;21(3):293-301.


Arendt T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience. 2001;102(4):723-65.

Einat H, Belmaker RH. The effects of inositol treatment in animal models of psychiatric disorders. J Affect Disord. 2001 Jan;62(1-2):113-21.


Kesavapany S, Lau KF, McLoughlin DM, Brownlees J, Ackerley S, Leigh PN, Shaw CE, Miller CC. p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction. Eur J Neurosci. 2001 Jan;13(2):241-7.
 

Lee D, Lee EK, Lee JH, Chang CS, Paik SR. Self-oligomerization and protein aggregation of alpha-synuclein in the presence of Coomassie Brilliant Blue. Eur J Biochem. 2001 Jan;268(2):295-301.

Dorrell S. Alzheimer's disease - a metallic problem. Drug Discov Today. 2001 Jan 1;6(2):61-62.

Esiri MM. Is an effective immune intervention for Alzheimer's disease in prospect? Trends Pharmacol Sci. 2001 Jan;22(1):2-3.

Morgan D. The intersection of Alzheimer's disease and typical aging. Neurobiol Aging. 2001 Jan-Feb;22(1):159-60; discussion 161-3.

Terry RD. Commentary. Copernicus revisited: amyloid beta in alzheimer disease. Neurobiol Aging. 2001 Jan-Feb;22(1):155; discussion 161-3.

Joseph J, Shukitt-Hale B, Denisova NA, Martin A, Perry G, Smith MA. Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol Aging. 2001 Jan-Feb;22(1):131-46.
 

Reed LA, Wszolek ZK, Hutton M. Phenotypic correlations in FTDP-17. Neurobiol Aging. 2001 Jan-Feb;22(1):89-107.

Duplan L, Michel B, Boucraut J, Barthellémy S, Desplat-Jego S, Marin V, Gambarelli D, Bernard D, Berthézène P, Alescio-Lautier B, Verdier JM. Lithostathine and pancreatitis-associated protein are involved in the very early stages of Alzheimer's disease. Neurobiol Aging. 2001 Jan-Feb;22(1):79-88. ,

Lehmann DJ, Wiebusch H, Marshall SE, Johnston C, Warden DR, Morgan K, Schappert K, Poirier J, Xuereb J, Kalsheker N, Welsh KI, Smith AD. HLA class I, II & III genes in confirmed late-onset Alzheimer's disease. Neurobiol Aging. 2001 Jan-Feb;22(1):71-7. ,

Bergamaschini L, Donarini C, Foddi C, Gobbo G, Parnetti L, Agostoni A. The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system. Neurobiol Aging. 2001 Jan-Feb;22(1):63-9.

Härtig W, Klein C, Brauer K, Schüppel KF, Arendt T, Bigl V, Brückner G. Hyperphosphorylated protein tau is restricted to neurons devoid of perineuronal nets in the cortex of aged bison. Neurobiol Aging. 2001 Jan-Feb;22(1):25-33.

Beauregard M, Chertkow H, Gold D, Bergman S. The impact of semantic impairment on word stem completion in Alzheimer's disease. Neuropsychologia. 2001;39(3):302-14.

Tsuji T, Shimohama S. Analysis of the proteomic profiling of brain tissue in Alzheimer's disease. Dis Markers. 2001;17(4):247-57.

Zuliani G, Ble' A, Zanca R, Munari MR, Zurlo A, Vavalle C, Atti AR, Fellin R. Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease. BMC Geriatr. 2001;1(1):5.

Guan ZZ, Miao H, Tian JY, Unger C, Nordberg A, Zhang X. Suppressed expression of nicotinic acetylcholine receptors by nanomolar beta-amyloid peptides in PC12 cells. J Neural Transm. 2001;108(12):1417-33.

Kaskie B, Knight BG, Liebig PS. Dementia policy revisited: an analysis of the state laws targeted towards individuals with Alzheimer's disease and other forms of dementia. J Aging Soc Policy. 2001;12(4):27-45.

Pasinetti GM, Ho L. From cDNA microarrays to high-throughput proteomics. Implications in the search for preventive initiatives to slow the clinical progression of Alzheimer's disease dementia. Restor Neurol Neurosci. 2001;18(2-3):137-42.

Mattson MP, Duan W, Pedersen WA, Culmsee C. Neurodegenerative disorders and ischemic brain diseases. Apoptosis. 2001 Feb-Apr;6(1-2):69-81.

Pasquier F, Grymonprez L, Lebert F, Van der Linden M. Memory impairment differs in frontotemporal dementia and Alzheimer's disease. Neurocase. 2001;7(2):161-71.

Mychack P, Rosen H, Miller BL. Novel applications of social-personality measures to the study of dementia. Neurocase. 2001;7(2):131-43.

Zill P, Engel R, Hampel H, Behrens S, Bürger K, Padberg F, Stübner S, Möller HJ, Ackenheil M, Bondy B. Polymorphisms in the apolipoprotein E (APOE) gene in gerontopsychiatric patients. Eur Arch Psychiatry Clin Neurosci. 2001;251(1):24-8. , ,

Fosslien E. Mitochondrial medicine--molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci. 2001 Jan;31(1):25-67.

Kostyszyn B, Cowburn RF, Seiger A, KjAEldgaard A, Sundström E. Expression of presenilin-1 and Notch-1 receptor in human embryonic CNS. Neuroscience. 2001;103(4):885-98.

Carnero Pardo C. [Are the new drugs for treatment of Alzheimer's disease useful?] Rev Neurol. 2001 Jan 16-31;32(2):176-9.

Guardado-Santervás P. [Controversies about new drugs for the treatment of dementia. An unfavourable view] Rev Neurol. 2001 Jan 16-31;32(2):172-5.

Emerich DF, Salzberg HC. Update on immunoisolation cell therapy for CNS diseases. Cell Transplant. 2001 Jan-Feb;10(1):3-24.

Jeong J, Chae JH, Kim SY, Han SH. Nonlinear dynamic analysis of the EEG in patients with Alzheimer's disease and vascular dementia. J Clin Neurophysiol. 2001 Jan;18(1):58-67.

Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer's disease. Neuroscience. 2001;103(2):373-83.

Baláspiri L, Langel U. Synthesis of of beta-amyloid precursor peptide and presenilin segments. J Pept Sci. 2001 Jan;7(1):58-60.

Weis C, Kaufmann WA, Humpel C. Lipid-mediated in vivo gene transfer replaces the loss of choline acetyltransferase activity after unilateral fimbria-fornix aspiration. Cell Transplant. 2001;10(8):681-8.

Lund TD, West TW, Tian LY, Bu LH, Simmons DL, Setchell KD, Adlercreutz H, Lephart ED. Visual spatial memory is enhanced in female rats (but inhibited in males) by dietary soy phytoestrogens. BMC Neurosci. 2001;2(1):20. ,

Licastro F, Pedrini S, Davis LJ, Caputo L, Tagliabue J, Savorani G, Cucinotta D, Annoni G. Alpha-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer disease: a short-term longitudinal study. Alzheimer Dis Assoc Disord. 2001 Jan-Mar;15(1):51-5. ,

Imamura K, Sawada M, Ozaki N, Naito H, Iwata N, Ishihara R, Takeuchi T, Shibayama H. Activation mechanism of brain microglia in patients with diffuse neurofibrillary tangles with calcification: a comparison with Alzheimer disease. Alzheimer Dis Assoc Disord. 2001 Jan-Mar;15(1):45-50.

Kato M, Meguro K, Sato M, Shimada Y, Yamazaki H, Saito H, Yamaguchi S, Yamadori A. Ideomotor apraxia in patients with Alzheimer disease: why do they use their body parts as objects? Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jan;14(1):45-52.

Koh JY. Zinc and disease of the brain. Mol Neurobiol. 2001 Aug-Dec;24(1-3):99-106.

Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer's disease. Drugs. 2001;61(1):41-52.

Kareken DA, Doty RL, Moberg PJ, Mosnik D, Chen SH, Farlow MR, Hutchins GD. Olfactory-evoked regional cerebral blood flow in Alzheimer's disease. Neuropsychology. 2001 Jan;15(1):18-29.

Parvizi J, Van Hoesen GW, Damasio A. The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann Neurol. 2001 Jan;49(1):53-66.


Smith MJ, Kwok JB, McLean CA, Kril JJ, Broe GA, Nicholson GA, Cappai R, Hallupp M, Cotton RG, Masters CL, Schofield PR, Brooks WS. Variable phenotype of Alzheimer's disease with spastic paraparesis. Ann Neurol. 2001 Jan;49(1):125-9.
 

Bertram L, Guénette S, Jones J, Keeney D, Mullin K, Crystal A, Basu S, Yhu S, Deng A, Rebeck GW, Hyman BT, Go R, McInnis M, Blacker D, Tanzi R. No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease. Ann Neurol. 2001 Jan;49(1):114-6. ,

Yoo BC, Fountoulakis M, Cairns N, Lubec G. Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis. 2001 Jan;22(1):172-9.

Inoue S. Basement membrane and beta amyloid fibrillogenesis in Alzheimer's disease. Int Rev Cytol. 2001;210:121-61.

Bu G. The roles of receptor-associated protein (RAP) as a molecular chaperone for members of the LDL receptor family. Int Rev Cytol. 2001;209:79-116.

Dobson CM. Protein folding and its links with human disease. Biochem Soc Symp. 2001;(68):1-26.

Ende N, Chen R, Ende-Harris D. Human umbilical cord blood cells ameliorate Alzheimer's disease in transgenic mice. J Med. 2001;32(3-4):241-7.

Okhotin VE, Kalinichenko SG. [Cells-chandeliers and axo-axonal inhibition in the neocortex, hippocampus, and the dentate gyrus] Morfologiia. 2001;119(3):7-23.

Lott IT, Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev. 2001;7(3):172-8.

Espejo C, Carrasco J, Hidalgo J, Penkowa M, Garcia A, Sáez-Torres I, Martínez-Cáceres EM. Differential expression of metallothioneins in the CNS of mice with experimental autoimmune encephalomyelitis. Neuroscience. 2001;105(4):1055-65.

Kéri S, Kálmán J, Kelemen O, Benedek G, Janka Z. Are Alzheimer's disease patients able to learn visual prototypes? Neuropsychologia. 2001;39(11):1218-23.

Kril JJ, Halliday GM. Alzheimer's disease: its diagnosis and pathogenesis. Int Rev Neurobiol. 2001;48:167-217.

Zhang JM, Hu GY. Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons. Neuroscience. 2001;105(3):663-9.

Cedazo-Mínguez A, Hamker U, Meske V, Veh RW, Hellweg R, Jacobi C, Albert F, Cowburn RF, Ohm TG. Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures. Neuroscience. 2001;105(3):651-61.

Vincent I, Bu B, Hudson K, Husseman J, Nochlin D, Jin L. Constitutive Cdc25B tyrosine phosphatase activity in adult brain neurons with M phase-type alterations in Alzheimer's disease. Neuroscience. 2001;105(3):639-50.

Near SE, Wang J, Hegele RA. Single nucleotide polymorphisms of the very low density lipoprotein receptor (VLDLR) gene. J Hum Genet. 2001;46(8):490-3.

Spada RS, Cento RM, Proto C, Ferri R, Roccasalva G, Toscano G, Cosentino FI, Lanzone A. Twenty-four-hour urinary free cortisol levels in vascular dementia and in Alzheimer's disease. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:363-7.

Panza F, Colacicco AM, Basile AM, Capurso C, D'Introno A, Mastroianni F, Scicutella G, Capurso A, Solfruzzi V. Impact of decreased frequency of apolipoprotein E epsilon4 allele on Alzheimer's disease in Southern Italy. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:299-306.

Nacmias B, Tedde A, Forleo P, Piacentini S, Latorraca S, Guarnieri BM, Ortenzi L, Bartoli A, Petruzzi C, Serio A, Sorbi S. Psychosis, serotonin receptor polymorphism and Alzheimer's disease. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:279-83.

Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001;18(12):891-8.

Greig N H, Utsuki T, Yu Q, Zhu X, Holloway H W, Perry T, Lee B, Ingram D K, Lahiri D K. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin. 2001;17(3):159-65.

Sugimoto H. Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem Rec. 2001;1(1):63-73.

Rioda WT, Nervetti A. [In Process Citation] Acta Biomed Ateneo Parmense. 2001;72(3-4):55-64.

Tyas SL. Alcohol use and the risk of developing Alzheimer's disease. Alcohol Res Health. 2001;25(4):299-306.

Sinczuk-Walczak H. [In Process Citation] Med Pr. 2001;52(6):479-81.


Camus JF, Nicolas S, Wenisch E, Morrone I, Blanchard F, Bakchine S. Implicit memory for words presented in short texts is preserved in Alzheimer's Disease. Rev Neurol (Paris). 2001;157 Suppl 10:52.

Bard F, Games D, Seubert P, Yednock T, Schenk D. Immunotherapeutic approach to the Alzheimer's disease. Rev Neurol (Paris). 2001;157 Suppl 10:31.

Petersen RC, Kanow C. Mild cognitive impairment - State of the art 2001. Rev Neurol (Paris). 2001;157 Suppl 10:29.

Stern Y. Imaging studies of aging and AD. Rev Neurol (Paris). 2001;157 Suppl 10:27-8.

Salamon G, Johnson N, Salamon Muryama N, Gitelman D, Weitraub S, Mesulam MM. Neuroradiology in patients followed for probable Alzheimer's disease. Rev Neurol (Paris). 2001;157 Suppl 10:27.

Dobson J. On the structural form of iron in ferritin cores associated with progressive supranuclear palsy and Alzheimer's disease. Cell Mol Biol (Noisy-le-grand). 2001;47 Online Pub:OL49-50.

Strle K, Zhou J H, Shen W H, Broussard S R, Johnson R W, Freund G G, Dantzer R, Kelley K W. Interleukin-10 in the brain. Crit Rev Immunol. 2001;21(5):427-49.

Reich EE, Markesbery WR, Roberts LJ, Swift LL, Morrow JD, Montine TJ. Quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Adv Exp Med Biol. 2001;500:253-6.

Szpak GM, Lechowicz W, Lewandowska E, Bertrand E, Wierzba-Bobrowicz T, Gwiazda E, Schmidt-Sidor B, Dymecki J. Neurones and microglia in central nervous system immune response to degenerative processes. Part 1: Alzheimer's disease and Lewy body variant of Alzheimer's disease. Quantitative study. Folia Neuropathol. 2001;39(3):181-92.

von Bernhardi R, Ramirez G. Microglia-astrocyte interaction in Alzheimer's disease: friends or foes for the nervous system? Biol Res. 2001;34(2):123-8.

Shastry BS. Molecular and cell biological aspects of Alzheimer disease. J Hum Genet. 2001;46(11):609-18.

Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord. 2001 Oct-Dec;15(4):169-73.

Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord. 2001 Oct-Dec;15(4):174-83.

Pohjasvaara T, Ylikoski R, Leskelä M, Kalska H, Hietanen M, Kaste M, Erkinjuntti T. Evaluation of various methods of assessing symptoms of cognitive impairment and dementia. Alzheimer Dis Assoc Disord. 2001 Oct-Dec;15(4):184-93.

Meguro K, Shimada M, Someya K, Horikawa A, Yamadori A. Hemispatial visual-searching impairment correlated with decreased contralateral parietal blood flow in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001 Oct-Dec;14(4):213-8.

Inoue S, Kisilevsky R. Beta-amyloid fibrils of Alzheimer's disease: pathologically altered, basement membrane-associated microfibrils? Ital J Anat Embryol. 2001;106(2 Suppl 1):93-102.

Grootendorst J, de Kloet ER, Dalm S, Oitzl MS. Reversal of cognitive deficit of apolipoprotein E knockout mice after repeated exposure to a common environmental experience. Neuroscience. 2001;108(2):237-47.

Adams I, Brauer K, Arélin C, Härtig W, Fine A, Mäder M, Arendt T, Brückner G. Perineuronal nets in the rhesus monkey and human basal forebrain including basal ganglia. Neuroscience. 2001;108(2):285-98.

Lehmann DJ, Williams J, Mcbroom J, Smith AD. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience. 2001;108(4):541-54.

Mack TG, Dayanandan R, Van Slegtenhorst M, Whone A, Hutton M, Lovestone S, Anderton BH. Tau proteins with frontotemporal dementia-17 mutations have both altered expression levels and phosphorylation profiles in differentiated neuroblastoma cells. Neuroscience. 2001;108(4):701-12.


Haugabook SJ, Le T, Yager D, Zenk B, Healy BM, Eckman EA, Prada C, Younkin L, Murphy P, Pinnix I, Onstead L, Sambamurti K, Golde TE, Dickson D, Younkin SG, Eckman CB. Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin. FASEB J. 2001 Jan;15(1):16-18.
 

Knuffman J, Mohsin F, Feder J, Grossberg GT. Differentiating Between Lewy Body Dementia and Alzheimer's Disease: A Retrospective Brain Bank Study. J Am Med Dir Assoc. 2001 Jul-Aug;2(4):146-148.

Westfall PH, Zaykin DV, Young SS. Multiple Tests for Genetic Effects in Association Studies. Methods Mol Biol. 2001;184:143-168.

Tavernarakis N, Xu K, Driscoll M. Execution of necrotic-like cell death in caenorhabditis elegans requires cathepsin d activity. ScientificWorldJournal. 2001 Jan 1;1(1 Suppl 3):139.

Altznauer F, Simon HU. CALPAIN IS A MAJOR REGULATOR OF NEUTROPHILS APOPTOSIS. ScientificWorldJournal. 2001 Jan 1;1(S3):91.

Holmlund L, Imreh G, Hallberg E, Iverfeldt K. Real time monitoring of apoptosis, induced by Beta-amyloid Peptide, in sh-sy5y neuroblastoma cells expressing a gfp-tagged nuclear pore protein. ScientificWorldJournal. 2001 Jan 1;1(1 Suppl 3):54.

Minagar A, Shapshak P, Heyes M, Sheremata WA, Fujimara R, Ownby R, Goodkin K, Eisdorfer K. Microglia and astrocytes in neuro-AIDS, alzheimers disease, and multiple sclerosis. ScientificWorldJournal. 2001 Jan 1;1(1 Suppl 3):69.

Libon DJ, Bogdanoff B, Leopold N, Hurka R, Bonavita J, Skalina S, Swenson R, Gitlin HL, Ball SK. Neuropsychological profiles associated with subcortical white matter alterations and Parkinson's disease: implications for the diagnosis of dementia. Arch Clin Neuropsychol. 2001 Jan;16(1):19-32.

Keltner NL, Zielinski AL, Hardin MS. Drugs used for cognitive symptoms of Alzheimer's disease. Perspect Psychiatr Care. 2001 Jan-Mar;37(1):31-4.

Lovestone S. It takes tau to tangle--the molecular biology of Alzheimer's disease. Trans Med Soc Lond. 2001-2002;118:54-6.

Dineley K. Society for Neuroscience--30th Annual Meeting. Alzheimer's disease: Therapeutics, targets and screens. IDrugs. 2001 Jan;4(1):1-5.

Fatope MO. Retigabine (ASTA Medica). IDrugs. 2001 Jan;4(1):93-8.

Lian Q, Ladner CJ, Magnuson D, Lee JM. Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex. Exp Neurol. 2001 Jan;167(1):158-65.

Younkin SG. Amyloid beta vaccination: reduced plaques and improved cognition. Nat Med. 2001 Jan;7(1):18-9.

Paschen W. Dependence of vital cell function on endoplasmic reticulum calcium levels: implications for the mechanisms underlying neuronal cell injury in different pathological states. Cell Calcium. 2001 Jan;29(1):1-11.

Moretti R, Torre P, Antonello RM, Cazzato G. Fronto-temporal dementia versus Alzheimer disease. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:273-8.

Spada RS, Ferri R, Roccasalva G, Toscano G, Cosentino FI. Lipoprotein(a), vascular dementia and Alzheimer's disease. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:369-73.

Fuschillo C, La Pia S, Campana F, Pinto A, De Simone L. Cognitive deficits in Alzheimer's disease: Treatment with acetylcholinesterase inhibitor agents. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:151-8.

Massaia M, Pallavicino Di Ceva A, Bo M, Cappa G, Zannella P, Persico D, Ferrario E, Fabris F. Risk factors for dementia of Alzheimer's type: A case-control, retrospective evaluation. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:253-9.

Vallotti B, Mossello E, Cantini C, Moretti G, Fumagalli S, Caleri V, Ungar A, Bruscoli M, Tilli S, Masotti G. Determinants of functional status in Alzheimer's disease and vascular dementia. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:419-28.

Licastro F. Genetic background of inflammatory molecules affects protein expression, the risk of developing Alzheimer's disease and cognitive decline. Arch Gerontol Geriatr. 2001 Jan;33 Suppl 1:227-34.

Ghisla MK, Marengoni A, Cossi S, Leonardi R. [Cognitive deficiency in internal medicine] Ann Ital Med Int. 2001 Apr-Jun;16(2):106-11.

Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev. 2001;(4):CD003160.

Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;(4):CD003159.

Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2001;(4):CD002852.

Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2001;(4):CD001747.

Scott HD, Laake K. Statins for the reduction of risk of Alzheimer's disease. Cochrane Database Syst Rev. 2001;(3):CD003160.

Lacritz LH, Cullum CM, Weiner MF, Rosenberg RN. Comparison of the hopkins verbal learning test-revised to the California verbal learning test in Alzheimer's disease. Appl Neuropsychol. 2001;8(3):180-4.

Robinson-Agramonte MA, Grazia De Simoni M, Serrano-Sánchez T, Llibre JJ, Hernández E. [Circulating cytokines in Alzheimer's disease] Rev Neurol. 2001 Jul 1-15;33(1):99-100.

Bertrand E, Lewandowska E, Szpak GM, Hoogenraad T, Blaauwgers HG, Czlonkowska A, Dymecki J. Neuropathological analysis of pathological forms of astroglia in Wilson's disease. Folia Neuropathol. 2001;39(2):73-9.

Szpak GM, Lewandowska E, Lechowicz W, Bertrand E, Wierzba-Bobrowicz T, Gwiazda E, Pasennik E, Kosno-Kruszewska E, Lipczynska-Lojkowska W, Bochynska A, Fiszer U. Lewy body variant of Alzheimer's disease and Alzheimer's disease: a comparative immunohistochemical study. Folia Neuropathol. 2001;39(2):63-71.